证券代码：300253 证券简称：卫宁健康 公告编号：2025-045 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 关于权益分派期间卫宁转债暂停转股的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 债券代码：123104，债券简称：卫宁转债 转股起止时间：2021 年 9 月 22 日至 2027 年 3 月 15 日 暂停转股时间：2025 年 5 月 22 日至 2024 年度权益分派股权登 记日止 恢复转股时间：公司 2024 年度权益分派股权登记日后的第一个 交易日 特此公告。 卫宁健康科技集团股份有限公司 董 事 会 二〇二五年五月二十一日 附件：《卫宁健康科技集团股份有限公司创业板向不特定对象发行可转换公司 债券募集说明书》中"转股价格的确定及调整"条款的规定 在本次发行之后，当公司发生派送股票股利、转增股本、增发新股（不包括 因本次发行的可转债转股而增加的股本）、配股以及派发现金股利等情况时，公 司将按上述条件出现的先后顺序，依次对转股价格进行累积调整（保留小数点后 两位，最后一位四舍五入）， ...

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 11.28 CNY for 2025 [2][7]. Core Views - The company is experiencing a short-term performance pressure due to deferred downstream demand, but it is expected to improve as the WiNEX product enters a rapid delivery phase [7]. - The company has achieved a significant market share of 13.4% in the core hospital system market in China, ranking first [7]. - The company is focusing on enhancing its operational quality, with a notable increase in cash flow from operating activities, which grew by 120.5% year-on-year [7]. Financial Summary - Total revenue for 2024 is projected at 2,782 million CNY, a decrease of 12.0% year-on-year, with a net profit of 88 million CNY, down 75.4% year-on-year [3][7]. - For 2025, the company expects revenue to increase to 3,147 million CNY, reflecting a growth rate of 13.1%, and net profit to rise significantly to 384 million CNY, indicating a growth rate of 336.7% [3][7]. - The company’s earnings per share (EPS) is projected to be 0.04 CNY in 2024, increasing to 0.17 CNY in 2025 [3][7]. Business Development - The company is actively developing its WiNEX product line and has made significant investments in AI applications, with R&D expenses accounting for 20.2% of revenue [7]. - The company has established a digital health application ecosystem, with subsidiaries generating revenues of 1.6 million CNY, 2.1 million CNY, and 1.9 million CNY respectively in 2024 [7]. - The company is enhancing its international presence, exemplified by the successful implementation of a project at the Macau Concordia Hospital [7].

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 11.28 CNY for 2025 [2][7]. Core Views - The company is experiencing a short-term performance pressure due to deferred downstream demand, but it is expected to improve as the WiNEX product enters a rapid delivery phase [7]. - The company has established itself as a leader in medical information technology, with significant market share and ongoing investments in AI and product development [7]. - Financial forecasts indicate a substantial recovery in net profit from 2025 onwards, with expected growth rates of 336.7% in 2025, 16.0% in 2026, and 15.7% in 2027 [7]. Financial Summary - Total revenue is projected to increase from 27.82 billion CNY in 2024 to 40.04 billion CNY in 2027, with a compound annual growth rate (CAGR) of approximately 12.8% from 2025 to 2027 [3][8]. - The net profit is expected to rise from 0.88 billion CNY in 2024 to 5.15 billion CNY in 2027, reflecting a significant recovery after a sharp decline in 2024 [3][8]. - The earnings per share (EPS) is forecasted to grow from 0.04 CNY in 2024 to 0.23 CNY in 2027, indicating a positive trend in profitability [3][8]. Business Development - The company is focusing on enhancing its WiNEX product line and expanding its digital health applications, which are expected to drive future growth [7]. - The company has achieved over 600 certifications in the medical information technology sector, establishing a robust and self-controlled technology system [7]. - The company is also making strides in international markets, with successful projects like the Macau Concordia Hospital [7].

Core Viewpoint - The company announced the results of the convertible bond repurchase, indicating that no bonds were repurchased during the designated period, which will not significantly impact its financial status or operational capabilities [1][2]. Group 1: Announcement of Convertible Bond Repurchase - The company published multiple announcements regarding the repurchase of its convertible bonds, allowing holders to sell their bonds back to the company at a price of 100.281 CNY per bond, including interest and tax [1][2]. - The repurchase period was specified to end on May 16, 2025, after which the company would not need to process any payments to bondholders [2]. Group 2: Repurchase Results and Impact - The total number of valid repurchase applications for the "卫宁转债" was reported as 0, resulting in a repurchase amount of 0 CNY [2]. - The company stated that the lack of repurchase will not have a significant effect on its financial condition, operational results, cash flow, or capital structure, and it will not impair its debt servicing ability or ongoing operations [2].

卫宁健康科技集团股份有限公司 关于卫宁转债回售结果的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 证券代码：300253 证券简称：卫宁健康 公告编号：2025-044 债券代码：123104 债券简称：卫宁转债 1、债券简称：卫宁转债 2、债券代码：123104 3、回售申报期：2025 年 5 月 12 日至 2025 年 5 月 16 日 4、回售价格：100.281 元/张（含息、税） 5、回售有效申报数量：0 张 6、回售金额：0 元（含息、税） 示性公告》（公告编号：2025-031）、《关于卫宁转债回售的第三次提 示性公告》（公告编号：2025-032）、《关于卫宁转债回售的第四次提 示性公告》（公告编号：2025-033）、《关于卫宁转债回售的第五次提 示性公告》（公告编号：2025-035）、《关于卫宁转债回售的第六次提 示性公告》（公告编号：2025-036）、《关于卫宁转债回售的第七次提 示性公告》（公告编号：2025-037）、《关于卫宁转债回售的第八次提 示性公告》（公告编号：2025-039）、《关于卫宁转债回售的 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2025-043 卫宁健康科技集团股份有限公司 关于股东持股在一致行动人内部转让计划的提示性公告 公司股东刘宁先生保证向公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容与信息披露义务人 提供的信息一致。 重要内容提示： 1、公司股东、董事刘宁先生的一致行动人通怡私募基金产品持 有公司股份 31,684,667 股，约占公司总股本的 1.43%，约占剔除公 司回购专户股份后总股本的 1.44%。 2、通怡私募基金产品拟自本公告披露之日起 15 个交易日后的 3 个月内（2025 年 6 月 11 日至 2025 年 9 月 10 日，窗口期不转让）通 过大宗交易方式将其持有的全部公司股份 31,684,667 股转让给刘宁 先生的配偶侯明华女士。侯明华女士持有通怡私募基金产品 100%的 份额。 3、本计划属于公司股东的一致行动人成员内部持股变动，刘宁 先生及其一致行动人合计持股数量和持股比例未发生变化，不涉及向 市场减持。 一、本计划概述 卫宁健康科技集团股份有限公司（简称"公司"）于近日收 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2025-042 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 关于卫宁转债恢复转股的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 公司股票自 2025 年 3 月 16 日至 2025 年 4 月 28 日连续三十个交 易日的收盘价格低于当期"卫宁转债"转股价格 17.45 元/股的 70%， 即 12.22 元/股，且"卫宁转债"处于最后两个计息年度。根据公司 《创业板向不特定对象发行可转换公司债券募集说明书》约定，"卫 宁转债"的有条件回售条款生效。 根据《深圳证券交易所上市公司自律监管指引第 15 号——可转 换公司债券》的相关规定，可转换公司债券实施回售的，应当暂停可 转换公司债券转股。经向深圳证券交易所申请，"卫宁转债"在回售 1、债券代码：123104；债券简称：卫宁转债 2、转股起止日期：2021年9月22日至2027年3月15日 3、暂停转股日期：2025年5月12日至2025年5月16日 4、恢复转股日期：2025年5月19日 申报期间暂停转股， ...

关于卫宁转债回售的第十次提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、回售价格：100.281 元/张（含息、税） 2、回售条件满足日：2025 年 4 月 28 日 证券代码：300253 证券简称：卫宁健康 公告编号：2025-041 债券代码：123104 债券简称：卫宁转债 卫宁健康科技集团股份有限公司 3、回售申报期：2025 年 5 月 12 日至 2025 年 5 月 16 日 4、发行人资金到账日：2025 年 5 月 21 日 5、回售款划拨日：2025 年 5 月 22 日 6、投资者回售款到账日：2025 年 5 月 23 日 7、回售申报期内，"卫宁转债"暂停转股 8、"卫宁转债"持有人有权选择是否进行回售，本次回售不具有 强制性 9、风险提示：持有人本次选择回售等同于以 100.281 元/张（含 当期利息）的价格卖出持有的"卫宁转债"。截至目前，"卫宁转债" 的收盘价格高于本次回售价格，投资者选择回售可能带来损失，敬请 投资者注意风险。 卫宁健康科技集团股份有限公司（以下简称"公司"）的股票自 2025 ...

Group 1 - The DRG/DIP concept declined by 3.30%, ranking among the top declines in the concept sector, with notable declines in companies such as Chuangying Huikang, ST Yilianzhong, and Jiahe Meikang [1][2] - The DRG/DIP concept experienced a net outflow of 4.92 billion yuan in main funds, with 19 stocks seeing net outflows, and 13 stocks with outflows exceeding 10 million yuan [2] - The stock with the highest net outflow was Donghua Software, with a net outflow of 1.26 billion yuan, followed by Chuangying Huikang, Weining Health, and Dian Diagnosis [2][3] Group 2 - The top stocks with net outflows in the DRG/DIP concept included Donghua Software (-3.97%), Chuangying Huikang (-6.76%), and Weining Health (-4.60%) [2][3] - Conversely, the stocks with net inflows included Huaping Co., Guoke Hengtai, and Wanda Information, with net inflows of 238.84 million yuan, 166.15 million yuan, and 121.00 million yuan respectively [2]

Core Viewpoint - The internet insurance sector has shown a positive performance with a 2.52% increase, ranking sixth among concept sectors, driven by significant gains in several key stocks [1][2]. Group 1: Sector Performance - As of May 14, the internet insurance concept rose by 2.52%, with 12 stocks increasing in value, including Tianli Technology, which hit a 20% limit up, and notable gains from Xinhua Insurance, Dongfang Fortune, and China Ping An, which rose by 6.50%, 5.03%, and 4.25% respectively [1]. - The sector's performance is part of a broader market trend, with other sectors like the China-Korea Free Trade Zone and shipping concepts also showing strong gains [2]. Group 2: Capital Flow - The internet insurance sector attracted a net inflow of 3.501 billion yuan, with 10 stocks receiving significant capital inflows, and 9 stocks seeing over 10 million yuan in net inflow [2]. - Dongfang Fortune led the net inflow with 1.957 billion yuan, followed by China Ping An and Xinhua Insurance with net inflows of 1.084 billion yuan and 242 million yuan respectively [2]. - The net inflow ratios for Tianli Technology, China Ping An, and Dongfang Fortune were 17.51%, 12.69%, and 9.95% respectively, indicating strong investor interest [3].